Pharmacogenetic Testing in Primary Care

NCT01600846 | Completed DMC

• 2 other identifiers: Pro000311222R01GM081416-04
• Study Type: observational
• Target: 400
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to further integrate pharmacogenetic (PGx) testing into clinical practice by educating physicians about pharmacogenetics and offering testing to their patients. Pharmacogenetic testing may help physicians choose the best drug and dosage for their patients which can reduce side effects, increase effectiveness, and improve patient adherence. Two clinics will be involved. One clinic will have a pharmacist on-site as a resource to physicians and to advise what patients may benefit from PGx testing; the other clinic will have a pharmacist on call. Patient and physician perspectives about PGx testing and their utilization will be examined via surveys. The investigators hypothesize that with education about PGx testing, more physicians will utilize testing.

Conditions

Pharmacogenetic Testing

Keywords

Pharmacogenetic testing; pharmacokinetics; Pharmacogenomics; genetics; pharmacy; drug response

Outcome Measures

Primary Outcomes (1)

• Use of PGx testing

  6 months, 12 months

Secondary Outcomes (1)

• Number of adverse drug reactions

  6 months, 12 months

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Physician population will be physicians practicing at the two clinics part of Duke University Medical Center Patient population will be patients who receive primary care at one of the two participating clinics.

You may qualify if:

• must be a patient or physician at one of the participating clinics
• patients must be prescribed a medication that has PGx testing available
• years of age or older
• English-speaking

Sponsors & Collaborators

• Duke University: lead
• National Institute of General Medical Sciences (NIGMS): collaborator

Study Sites (1)

Duke University Medical Center

Durham, North Carolina, 27708, United States

Location

Study Officials

• Susanne Haga, PhD

  Duke Unviersity Medical Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 15, 2012
• First Posted: May 17, 2012
• Study Start: December 1, 2012
• Primary Completion: July 1, 2013
• Study Completion: July 1, 2013
• Last Updated: July 28, 2017

Record last verified: 2014-08

Locations

US (1)